Bolduan, Vanessa; Palzer, Kim-Alicia; Ries, Frederic et al.
KSRP Deficiency Attenuates the Course of Pulmonary Aspergillosis and Is Associated with the Elevated Pathogen-Killing Activity of Innate Myeloid Immune CellsCELLS. Bd. 13. H. 24. 2024
Bumma, Naresh; Richter, Joshua; Jagannath, Sundar et al.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 22. 2024
Bumma, Naresh; Richter, Joshua; Jagannath, Sundar et al.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma (vol 42, pg 2702, 2024)JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 33. 2024 S. 4001-4001
Finke, Juergen; Schmoor, Claudia; Ayuk, Francis et al.
Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)BONE MARROW TRANSPLANTATION. Bd. 59. H. 7. 2024 S. 936-941
Finke, Juergen; Schmoor, Claudia; Ayuk, Francis et al.
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) (MAR, 10.1038/s41409-024-02264-9, 2024)BONE MARROW TRANSPLANTATION. Bd. 59. H. 8. 2024 S. 1204-1204
Tournilhac, Olivier; Altmann, Bettina; Friedrichs, Birte et al.
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 32. 2024
Wölfel, T
Lymphoma Vaccines: Background and PerspectivesCancer Immunotherapy. Springer 2024
Penack, Olaf; Dreger, Peter; Ajib, Salem et al.
Management of Patients Undergoing CAR-T Cell Therapy in GermanyONCOLOGY RESEARCH AND TREATMENT. Bd. 47. H. 3. 2024
Ruecker, Frank G.; Bullinger, Lars; Cocciardi, Sibylle et al.
Measurable residual disease monitoring in AML with <i>FLT3</i>-ITD treated with intensive chemotherapy plus midostaurinBLOOD ADVANCES. Bd. 8. H. 23. 2024 S. 6067-6080
Jilg, Stefanie; Schwaab, Juliana; Sockel, Katja et al.
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patientsANNALS OF HEMATOLOGY. Bd. 103. H. 10. 2024 S. 4065-4077